Fig. 7
STn-targeted NPs loaded with dsRNA-galectin-3 and/or dsRNA-ST6GalNAc-I increase 5-FU therapeutic effect in vivo. A Schematic representation of the in vivo experimental design and treatment schedule. On day-10, mice were brought from the vivarium to the laboratory animal research facility. On day zero, 1 × 106 MKN45-ST6GalNAc-I cells were injected subcutaneously in the right flank of mice. On day 20, mice were treated intravenously with sTn-targeted NPs and intraperitoneally with 25 mg/Kg of 5-FU for 3 weeks, 3 times a week and; on day 45 mice were euthanized. B Tumor growth of MKN45-ST6GalNAc-I-overexpressing cells in Balb/c nude mice treated or not with 5-FU (25 mg/Kg) plus sTn-targeted NPs loaded with dsRNA-galectin-3, dsRNA-ST6GalNAc-I, dsRNA-random or a (1:1) combination of dsRNA-ST6GalNAc-I and dsRNA-galectin-3. C Immunohistochemical staining of sTn and galectin-3 in MKN45-ST6GalNAc-I-derived tumors treated or not with 5-FU (25 mg/Kg) plus sTn-targeted NPs loaded with dsRNA-galectin-3, dsRNA-ST6GalNAc-I, dsRNA-random or a (1:1) combination of dsRNA-ST6GalNAc-I and dsRNA-galectin-3, bar = 20 μm. Data are the mean ± SEM (C) or representative (D) of n = 6, **p < 0.01 and ****p < 0.0001